Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 300-399

300. I.M. Brook, P.V. Hatton, “Glass-ionomers: bioactive implant materials,” Biomaterials 19(March 1998):565-571.

301. E.J. Harper, “Bioactive bone cements,” Proc. Inst. Mech. Eng. [H] 212(1998):113-120.

302. C.R. Anderegg, D.C. Alexander, M. Freidman, “A bioactive glass particulate in the treatment of molar furcation invasions,” J. Periodontol. 70(April 1999):384-387.

303. S.R. MacNeill, C.M. Cobb, J.W. Rapley, A.G. Glaros, P. Spencer, “In vivo comparison of synthetic osseous graft materials. A preliminary study,” J. Clin. Periodontol. 26(April 1999):239-245.

304. S.P. Bendall, M. Gaies, C. Frondoza, R.H. Jinnah, D.S. Hungerford, “Effect of particulate bioactive glass on human synoviocyte cultures,” J. Biomed. Mater. Res. 41(5 September 1998):392-397.

305. K.B. Kashuk, E. Haber, “Tendon and ligament prostheses,” Clin. Podiatry 1(April 1984):131-143.

306. Anthony G. Gristina, Quentin N. Myrvik, Lawrence X. Webb, “Biomaterial surfaces: Tissue cells and bacteria, compatibility versus infection,” in Richard Skalak, C. Fred Fox, eds., Tissue Engineering, Alan R. Liss, Inc., New York, 1988, pp. 99-107.

307. D.J. Farrar, J.D. Hill, L.A. Gray Jr., D.G. Pennington, L.R. McBride, W.S. Pierce, W.E. Pae, B. Glenville, D. Ross, T.A. Galbraith, G.L. Zumbro, “Heterotopic prosthetic ventricles as a bridge to cardiac transplantation. A multicenter study in 29 patients,” N. Engl. J. Med. 318(February 1988):333-340.

308. Artificial Heart issue, JAMA 259(1988):849 et seq.

309. M.M. Slusher, Q.N. Myrvik, J.C. Lewis, A.G. Gristina, “Extended-wear lenses, biofilm, and bacterial adhesion,” Arch. Ophthalmol. 105(January 1987):110-115.

310. J. Dankert, A.H. Hogt, J. Feijen, “Biomedical polymers: bacterial adhesion, colonization, and infection,” CRC Crit. Rev. Biocompat. 2(1986):219-301. See also: A.H. Hogt, J. Dankert, C.E. Hulstaert, J. Feijen, “Cell surface characteristics of coagulase-negative staphylococci and their adherence to fluorinated poly(ethylenepropylene),” Infect. Immun. 51(January 1986):294-301; A.H. Hogt, J. Dankert, J. Feijen, “Adhesion of coagulase-negative staphylococci to methacrylate polymers and copolymers,” J. Biomed. Mater. Res. 20(April 1986):533-545.

311. T. Albrektsson, “The response of bone to titanium implants,” CRC Crit. Rev. Biocompat. 1(1985):53 et seq.

312. G.D. Christiansen, W.A. Simpson, E.H. Beachey, “Adhesion of bacteria to animal tissues: complex mechanisms,” in D.C. Savage, M. Fletcher, eds., Bacterial Adhesion: Mechanisms and Physiological Significance, Plenum Press, New York, pp. 279 et seq.

313. A.L. Bisno, F.A. Waldvogel, eds., Infections Associated with Indwelling Medical Devices, American Society for Microbiology, Washington DC, 1989.

314. “Spire’s Ion-Beam Applications,” in Joan Zimmermann, ed., BMDO Technologies for Biomedical Applications, report prepared by the National Technology Transfer Center, Washington Operations for the Ballistic Missile Defense Organization, The Pentagon, Washington DC 20301-7100, 1997, pp. 72-73.

315. Y.F. Missirlis, W. Lemm, eds., Modern Aspects of Protein Adsorption on Biomaterials, Kluwer Academic Publishers, New York, 1991.

316. N. Crawford, Interaction of Cells With Natural and Foreign Surfaces, Plenum Publ., New York, 1986.

317. C. Picioreanu, M.C. van Loosdrecht, J.J. Heijnen, “Mathematical modeling of biofilm structure with a hybrid differential-discrete cellular automaton approach,” Biotechnol. Bioeng. 58(5 April 1998):101-116.

318. Y.H. An, R.J. Friedman, “Concise review of mechanisms of bacterial adhesion to biomaterial surfaces,” J. Biomed. Mater. Res. 43(Fall 1998):338-348.

319. J.D. Bryers, F. Drummond, “Local macromolecule diffusion coefficients in structurally non-uniform bacterial biofilms using fluorescence recovery after photobleaching (FRAP),” Biotechnol. Bioeng. 60(20 November 1998):462-473.

320. J.R. Lawrence, D.R. Korber, B.D. Hoyle, J.W. Costerton, D.E. Caldwell, “Optical sectioning of microbial biofilms,” J. Bacteriol. 173(October 1991):6558-6567.

321. D. DeBeer, P. Stoodley, Z. Lewandowski, “Liquid flow in heterogeneous biofilms,” Biotechnol. Bioeng. 44(1994):636-641.

322. B.A. Sanford, A.W. de Feijter, M.H. Wade, V.L. Thomas, “A dual fluorescence technique for visualization of Staphylococcus epidermidis biofilm using scanning confocal laser microscopy,” J. Ind. Microbiol. 16(January 1996):48-56.

323. S. Moller, A.R. Pedersen, L.K. Poulsen, E. Arvin, S. Molin, “Activity and three-dimensional distribution of toluene-degrading Pseudomonas putida in a multispecies biofilm assessed by quantitative in situ hybridization and scanning confocal laser microscopy,” Appl. Environ. Microbiol. 62(December 1996):4632-4640.

324. C.R. Jones, M.R. Adams, P.A. Zhdan, A.H. Chamberlain, “The role of surface physicochemical properties in determining the distribution of the autochthonous microflora in mineral water bottles,” J. Appl. Microbiol. 86(June 1999):917-927.

325. M.W. Mittelman, “Structure and functional characteristics of bacterial biofilms in fluid processing operations,” J. Dairy Sci. 81(October 1998):2760-2764.

326. M.J. Elder, F. Stapleton, E. Evans, J.K. Dart, “Biofilm-related infections in ophthalmology,” Eye 9(1995):102-109.

327. S.R. Ell, “Candida, the cancer of silastic,” J. Laryngol. Otol. 110(March 1996):240-242.

328. J.W. Costerton, Philip S. Stewart, E.P. Greenberg, “Bacterial Biofilms: A Common Cause of Persistent Infections,” Science 284(21 May 1999):1318-1322.

329. T.J. Marrie, J. Nelligan, J.W. Costerton, “A scanning and transmission electron microscopic study of an infected endocardial pacemaker lead,” Circulation 66(December 1982):1339-1341.

330. J.C. Nickel, I. Ruseska, J.B. Wright, J.W. Costerton, “Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material,” Antimicrob. Agents Chemother. 27(April 1985):619-624.

331. A.E. Khoury, K Lam, B.D. Ellis, J.W. Costerton, “Prevention and control of bacterial infections associated with medical devices,” Am. Soc. Artif. Intern. Organs J. 38(July-September 1992):M174-M178.

332. N.K. Karamanos, A. Syrokou, H.S. Panagiotopoulou, E.D. Anastassiou, G. Dimitracopoulos, “The major 20-kD polysaccharide of Staphylococcus epidermidis extracellular slime and its antibodies as powerful agents for detecting antibodies in blood serum and differentiating among slime-positive and -negative S. epidermidis and other staphylococci species,” Arch. Biochem. Biophys. 342(15 June 1997):389-395.

333. A. Razatos, Y.L. Ong, M.M. Sharma, G. Georgiou, “Molecular determinants of bacterial adhesion monitored by atomic force microscopy,” Proc. Natl. Acad. Sci. (USA) 95(15 September 1998):11059-11064; “Evaluating the interaction of bacteria with biomaterials using atomic force microscopy,” J. Biomater. Sci. Polym. Ed. 9(December 1998):1361-1373.

334. R.J. Palmer Jr., C. Sternberg, “Modern microscopy in biofilm research: confocal microscopy and other approaches,” Curr. Opin. Biotechnol. 10(June 1999):263-268.

335. D.G. Davies, A.M. Chakrabarty, G.G. Geesey, “Exopolysaccharide production in biofilms: substratum activation of alginate gene expression by Pseudomonas aeruginosa,” Appl. Environ. Microbiol. 59(April 1993):1181-1186.

336. H. Akiyama, O. Yamasaki, H. Kanzaki, J. Tada, J. Arata, “Effects of sucrose and silver on Staphylococcus aureus biofilms,” J. Antimicrob. Chemother. 42(November 1998):629-634.

337. B.L. Illingworth, K. Tweden, R.F. Schroeder, J.D. Cameron, “In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis,” J. Heart Valve Dis. 7(September 1998):524-530; J.W. Costerton, “In response to: ...,” J. Heart Valve Dis. 8(May 1999):346-348 (Letter); A. Brutel de la Riviere, K.M. Dossche, D.E. Birnbaum, R. Hacker, “First clinical experience with a mechanical valve with silver coating,” J. Heart Valve Dis. 9(January 2000):123-129, 129-130 (discussion); S. Bertrand, R. Houel, E. Vermes, C. Soustelle, M.L. Hillion, D. Loisance, “Preliminary experience with Silzone-coated St. Jude medical valves in acute infective endocarditis,” J. Heart Valve Dis. 9(January 2000):131-134; R.G. Seipelt, J.F. Vazquez-Jimenez, I.M. Seipelt, A. Franke, K. Chalabi, F.A. Schoendube, B.J. Messmer, “The St. Jude ‘Silzone’ valve: midterm results in treatment of active endocarditis,” Ann. Thorac. Surg. 72(September 2001):758-762, 762-763 (discussion).

338. T. Bechert, M. Boswald, S. Lugauer, A. Regenfus, J. Greil, J.P. Guggenbichler, “The Erlanger silver catheter: in vitro results for antimicrobial activity,” Infection 27(1999):S24-S29 (Suppl 1); W. Rosch, S. Lugauer, “Catheter-associated infections in urology: possible use of silver-impregnated catheters and the Erlanger silver catheter,” Infection 27(1999):S74-S77.

339. H. Liedberg, T. Lundeberg, “Silver coating of urinary catheters prevents adherence and growth of Pseudomonas aeruginosa,” Urol. Res. 17(1989):357-358.

340. M.K. Dasgupta, “Silver peritoneal catheters reduce bacterial colonization,” Adv. Perit. Dial. 10(1994):195-198.

341. J. Nakada, M. Kawahara, S. Onodera, Y. Oishi, “Clinical study of Silver Lubricath Foley catheter,” Hinyokika Kiyo 42(June 1996):433-438. In Japanese.

342. D.J. Stickler, N.S. Morris, T.J. Williams, “An assessment of the ability of a silver-releasing device to prevent bacterial contamination of urethral catheter drainage systems,” Br. J. Urol. 78(October 1996):579-588.

343. J.W. Leung, G.T. Lau, J.J. Sung, J.W. Costerton, “Decreased bacterial adherence to silver-coated stent material: an in vitro study,” Gastrointest. Endosc. 38(May-June 1992):338-340.

344. S.C. Malaisrie, S. Malekzadeh, J.F. Biedlingmaier, “In vivo analysis of bacterial biofilm formation on facial plastic bioimplants,” Laryngoscope 108(November 1998):1733-1738.

345. J. Olsson, Y. van der Heijde, K. Holmberg, “Plaque formation in vivo and bacterial attachment in vitro on permanently hydrophobic and hydrophilic surfaces,” Caries Res. 26(1992):428-433.

346. V. DiTizio, G.W. Ferguson, M.W. Mittelman, A.E. Khoury, A.W. Bruce, F. DiCosmo, “A liposomal hydrogel for the prevention of bacterial adhesion to catheters,” Biomaterials 19(October 1998):1877-1884.

347. B. Jansen, W. Kohnen, “Prevention of biofilm formation by polymer modification,” J. Ind. Microbiol. 15(October 1995):391-396.

348. Daniel P. Stites, Abba I. Terr, Tristram G. Parslow, eds., Medical Immunology, 9th Edition, Appleton & Lange, New York, 1997.

349. William E. Paul, ed., Fundamental Immunology, Fourth Edition, Lippincott Williams & Wilkins Publishers, New York, 1998.

350. Janis Kuby, Immunology, Third Edition, W.H. Freeman and Company, New York, 1998.

351. Peter J. Delves, Ivan M. Roitt, eds., The Encyclopedia of Immunology, Academic Press, New York, 1998.

352. Gregory Beck, Gail S. Habicht, “Immunity and the Invertebrates,” Scientific American 275(November 1996):60-64.

353. Wayne M. Becker, David W. Deamer, The World of the Cell, Second Edition, Benjamin/Cummings Publishing Company, Redwood City CA, 1991.

354. Charles A. Janeway, Jr., “How the Immune System Recognizes Invaders,” Scientific American (September 1993):72-79.

356. D. Gray, S. Bergthorsdottir, D. van Essen, M. Wykes, J. Poudrier, K. Siepmann, “Observations on memory B-cell development,” Semin. Immunol. 9(August 1997):249-254.

357. S. Han, B. Zheng, Y. Takahashi, G. Kelsoe, “Distinctive characteristics of germinal center B cells,” Semin. Immunol. 9(August 1997):255-260.

358. I.C.M. MacLennan, M. Casamayor-Palleja, K.M. Toellner, A. Gulbranson-Judge, J. Gordon, “Memory B-cell clones and the diversity of their members,” Semin. Immunol. 9(August 1997):229-234.

359. M.G. McHeyzer-Williams, R. Ahmed, “B cell memory and the long-lived plasma cell,” Curr. Opin. Immunol. 11(April 1999):172-179.

360. Philippa Marrack, John W. Kappler, “How the Immune System Recognizes the Body,” Scientific American (September 1993):80-89.

361. Robert Berkow, Mark H. Beers, Andrew J. Fletcher, eds., The Merck Manual of Medical Information, Merck Research Laboratories, Whitehouse Station NJ, 1997.

362. C.A. Michie, A. McLean, C. Alcock, P.C. Beverley, “Lifespan of human lymphocyte subsets defined by CD45 isoforms,” Nature 360(1992):264-265.

363. D.F. Tough, J. Sprent, “Life span of naive and memory T cells,” Stem Cells 13(May 1995):242-249; “Turnover of naive- and memory-phenotype T cells,” J. Exp. Med. 179(1 April 1994):1127-1135.

364. Rafi Ahmed, David Gray, “Immunological Memory and Protective Immunity: Understanding Their Relation,” Science 272(5 April 1996):54-60.

365. J. Sprent, D.F. Tough, S. Sun, “Factors controlling the turnover of T memory cells,” Immunol. Rev. 156(April 1997):79-85.

366. R.W. Dutton, L.M. Bradley, S.L. Swain, “T cell memory,” Annu. Rev. Immunol. 16(1998):201-223.

367. D.L. Farber, “Differential TCR signaling and the generation of memory T cells,” J. Immunol. 160(15 January 1998):535-539.

368. L.S. Davis, P.E. Lipsky, “Disordered differentiation of memory T cells in rheumatoid arthritis,” Rev. Rhum. Engl. Ed. 65(May 1998):291-296. See also: L.S. Davis, H. Schulze-Koops, P.E. Lipsky, “Human CD4+ T cell differentiation and effector function: implications for autoimmunity,” Immunol. Res. 19(1999):25-34.

369. A.D. Weinberg, A.T. Vella, M. Croft, “OX-40: Life beyond the effector T cell stage,” Semin. Immunol. 10(December 1998):471-480.

370. A.A. Freitas, B. Rocha, “Peripheral T cell survival,” Curr. Opin. Immunol. 11(April 1999):152-156; Chia Chi Ku, Masaaki Murakami, Akemi Sakamoto, John Kappler, Philippa Marrack, “Control of Homeostasis of CD8+ Memory T Cells by Opposing Cytokines,” Science 288(28 April 2000):675-678.

371. Ivan M. Roitt, Jonathan Brostoff, David K. Male, Immunology, Gower Medical Publishing, New York, 1989.

372. H.G. Rammensee, P.J. Fink, M.J. Bevan, “Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen,” J. Immunol. 133(November 1984):2390-2396.

373. J.M. Thomas, F.M. Carver, P.R. Cunningham, L.C. Olson, F.T. Thomas, “Kidney allograft tolerance in primates without chronic immunosuppression–the role of veto cells,” Transplantation 51(January 1991):198-207.

374. T. Tscherning, M.H. Claesson, “Veto suppression: the peripheral way of T cell tolerization,” Exp. Clin. Immunogenet. 10(1993):179-188.

375. J.M. Thomas, K.M. Verbanac, F.M. Carver, J. Kasten-Jolly, C.E. Haisch, U. Gross, J.P. Smith, “Veto cells in transplantation tolerance,” Clin. Transplant. 8(April 1994):195-203.

376. I.M. Jacobsen, M.H. Claesson, “Veto cell suppression mechanisms in the prevention of allograft rejection,” APMIS 106(March 1998):345-353.

377. J.F. George, J.M. Thomas, “The molecular mechanisms of veto mediated regulation of alloresponsiveness,” J. Mol. Med. 77(July 1999):519-526.

378. U.D. Staerz, Y. Qi, “Treatment of an autoimmune disease with `classical’ T cell veto: a proposal,” J. Clin. Immunol. 19(July 1999):195-202.

379. Y. Qi, R. Berg, M.A. Singleton, J.E. Debrick, U.D. Staerz, “Hybrid antibody mediated veto of cytotoxic T lymphocyte responses,” J. Exp. Med. 183(1 May 1996):1973-1980.

380. Y. Qi, U.D. Staerz, “Specific inhibition of CD4+ T lymphocytes by a hybrid antibody,” Nat. Biotechnol. 16(March 1998):271-275.

381. R.F. Rich, W.R. Green, “Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells,” J. Virol. 73(May 1999):3826-3834.

382. Physicians’ Desk Reference, 48th Edition, Medical Economics Data Production Company, Montvale, NJ, 1994.

383. J.F. Borel, “The mode of action of immunosuppressive drugs,” Jpn. J. Ophthalmol. 31(1987):521-531.

384. A.D. Hess, P.M. Colombani, A.H. Esa, “Cyclosporine and the immune response: basic aspects,” Crit. Rev. Immunol. 6(1986):123-149.

385. N. Broeders, K.M. Wissing, A. Crusiaux, P. Kinnaert, P. Vereerstraeten, D. Abramowicz, “Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients,” J. Am. Soc. Nephrol. 9(August 1998):1521-1525.

386. R.H. Dennin, E. Schulz, K. Sack, K. Dalhoff, J. Hoyer, “Influence of immunosuppressive therapy with azathioprine and prednisolone on serum-immunoglobulin concentration in renal transplanted patients,” Klin. Wochenschr. 63(4 November 1985):1110-1116.

387. B. Hausen, R.E. Morris, “Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies,” Clin. Chest Med. 18(June 1997):353-366.

388. F. Xiao, A.S. Chong, P. Foster, H. Sankary, L. McChesney, G. Koukoulis, J. Yang, D. Frieders, J.W. Williams, “Leflunomide controls rejection in hamster to rat cardiac xenografts,” Transplantation 58(15 October 1994):828-834.

389. S. Nihira, “Immune intervention by peptides having a MHC class II binding motif –application of MHC blockers to autoimmune disease models,” Nippon Rinsho 55(June 1997):1525-1530. In Japanese.

390. A. Faith, C.A. Akdis, M. Akdis, A. Joss, D. Wymann, K. Blaser, “An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling,” J. Immunol. 162(1 February 1999):1836-1842.

391. A.A. Vandenbark, Y.K. Chou, D.N. Bourdette, R. Whitham, G.A. Hashim, H. Offner, “T cell receptor peptide therapy for autoimmune disease,” J. Autoimmun. 5(April 1992):83-92 (Suppl A).

392. H.C. O’Neill, “Effects of anti-class I antibodies on proliferation of murine T lymphocytes,” Cell Immunol. 112(March 1988):236-243.

393. N. Amirayan, C. Vernet, P. Machy, “Class I-specific antibodies inhibit proliferation in primary but not secondary mouse T cell responses,” J. Immunol. 148(1 April 1992):1971-1978.

394. M. Ropke, C. Ropke, M.H. Claesson, “T-cell activation. VI. Inhibitory and stimulatory effects of anti-major histocompatibility complex class I antibodies in allogeneic mixed lymphocyte culture,” Immunology 79(June 1993):263-269.

395. H. DerSimonian, L. Pan, C. Yatko, A. Rodrigue-Way, E. Johnson, A.S. Edge, “Human anti-porcine T cell response: blocking with anti-class I antibody leads to hyporesponsiveness and a switch in cytokine production,” J. Immunol. 162(15 June 1999):6993-7001.

396. R.M. Smith, Z.K. Chen, R. Foulkes, S.M. Metcalfe, D.C. Wraith, “Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody,” Transplantation 64(15 August 1997):525-528.

397. N.E. Saxton, R.V. Hallaway, H.M. Ladyman, B.T. Janczynski, A.M. Nesbitt, K. Zinkewich-Peotti, R. Smith, R. Foulkes, “Anti-major histocompatibility complex class II treatment prevents graft rejection in the hamster-to-rat cardiac xenograft,” Transplantation 67(27 June 1999):1599-1606.

398. N.L. Ascher, “Amelioration of acute GVHD disease and reestablishment of tolerance by short term treatment with anti TCR antibody,” Liver Transpl. Surg. 1(July 1995):257-258.

399. K. Dehghanpisheh, J.J. Marchalonis, “Retrovirally induced mouse anti-TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens,” Scand. J. Immunol. 45(June 1997):645-654.


Last updated on 16 April 2004